Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

2.
3.

An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.

Shin KH, Lim KS, Lee H, Jang IJ, Yu KS.

Invest New Drugs. 2014 Aug;32(4):636-43. doi: 10.1007/s10637-014-0068-7. Epub 2014 Jan 28.

PMID:
24468886
4.

Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects.

Borleffs JC, Bosschaert M, Vrehen HM, Schneider MM, van Strijp J, Small MK, Borkett KM.

Clin Ther. 1998 Jul-Aug;20(4):722-36.

PMID:
9737832
5.

Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers.

Shin KH, Kim TE, Lim KS, Yoon SH, Cho JY, Kim SE, Park KM, Shin SG, Jang IJ, Yu KS.

BioDrugs. 2013 Apr;27(2):149-58. doi: 10.1007/s40259-013-0010-0.

PMID:
23359067
6.

Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.

Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K.

BioDrugs. 2009;23(1):43-51. doi: 10.2165/00063030-200923010-00005.

PMID:
19344191
8.

Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.

Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, Janulionis V.

Int J Clin Pharmacol Ther. 2009 Apr;47(4):275-82.

PMID:
19356394
9.
10.
11.

Pharmacokinetics and pharmacodynamics of pegfilgrastim.

Yang BB, Kido A.

Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Review.

PMID:
21456630
12.

Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.

Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, Hirsch J, Mahoney A, Carrell J, Boyd E, Grzegorzewski KJ.

Pharm Res. 2002 Nov;19(11):1720-9.

PMID:
12458679
13.
14.

Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.

Buchner A, Lammerich A, Abdolzade-Bavil A, Müller U, Bias P.

Curr Med Res Opin. 2014 Dec;30(12):2523-33. doi: 10.1185/03007995.2014.962131. Epub 2014 Sep 25.

PMID:
25251999
15.

Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Scholz M, Engel C, Apt D, Sankar SL, Goldstein E, Loeffler M.

Cell Prolif. 2009 Dec;42(6):823-37. doi: 10.1111/j.1365-2184.2009.00641.x. Epub 2009 Sep 24.

PMID:
19780759
16.

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G.

J Clin Oncol. 2000 Jul;18(13):2522-8.

PMID:
10893282
17.

Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects.

Matsuguma K, Matsuki S, Eunhee C, Watanabe A, Tanaka A, Sakamoto K, Takeshita H, Hitaka A, Shigetome K, Kimura M, Miyamoto A, Irie S, Kaneko D, Ohnishi A.

Drug Dev Ind Pharm. 2015 Mar;41(3):470-5. doi: 10.3109/03639045.2013.879721. Epub 2014 Jan 28.

PMID:
24471477
18.

Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.

Sveikata A, Gumbrevičius G, Seštakauskas K, Kregždytė R, Janulionis V, Fokas V.

Medicina (Kaunas). 2014;50(3):144-9. doi: 10.1016/j.medici.2014.08.001. Epub 2014 Aug 13.

19.

Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK.

J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42.

PMID:
11677930
20.

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.

Kim TE, Lim KS, Park MK, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

Clin Ther. 2012 Sep;34(9):1986-98. doi: 10.1016/j.clinthera.2012.08.006. Epub 2012 Sep 1.

PMID:
22943970

Supplemental Content

Support Center